Lance Liotta, Co-Director, Applied Proteomics and Molecular Medicine, and Emanuel Petricoin, III, Co-Director, Applied Proteomics and Molecular Medicine, received $1,339,358 from the U.S. Department of the Army for a study of HER2+ breast cancer.
The researchers have two goals for this project.
First, they aim to establish and optimize the quantitative cut point assay levels for polymerase Chain Reaction (pCR) for HER2+ breast cancer.
Second, they aim to independently and blindly validate the test on a retrospective cohort of tumors from patients receiving standard-of-care HER2+ neoadjuvant multimodality treatment series conducted at the Rutgers Cancer Center.
Funding for this project began in February 2021 and will end in late January 2024.
###